-
Prague’s Concert for the Future Kicks Off on Wenceslas Square
-
Apple Watch Live Rewind and Siri Recap: Privacy Concerns and Social Awkwardness
-
Prince William and Princess of Wales to Announce Earthshot Prize Winners in Mumbai
-
Rob Green Transforms Nottingham Central Library into Intimate Stage for Undercover Tour Finale
-
Indonesia Forest Fires: Health Crisis, Diplomatic Strains and the Search for Solutions
-
Proposed Fiscal Anchor Threatens South Africa’s Constitutional Rights Amid Health Crisis
-
BYD Dolphin G Leasing Deal: Plug-in Hybrid Supermini Available from £174 a Month
-
Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities
-
JUEL Group Expands from Real Estate to Hospitality with Hyatt Centric Malta Opening
-
Three Inaugural CombatX Champions Crowned at BRAVE CF Road to BRAVE Event in Hungary
-
French Economy Shrinks 0.1% as Consumer Confidence Slumps
-
China's Factory Activity Contracts as Export Orders Weaken
-
Wall Street Ends Turbulent Week Higher Despite Inflation and AI Jitters
-
US Retail Sales and Fed Minutes Set Up a Critical Test for Consumers
-
Kansas City Fed Chief Says Inflation Is Still Running Too Hot
-
Oil Heads for Second Weekly Loss as Supply Surplus Emerges
First person vaccinated during trial of new Ebola jab
A volunteer was injected on Friday with the first dose of a rapidly developed vaccine targeting the Bundibugyo strain of Ebola driving a deadly outbreak in the Democratic Republic of Congo, Oxford University said.
More than 1,000 people have been killed in the DRC and Uganda since the outbreak emerged in May, according to the World Health Organization.
Researchers and health organisations have since been racing to get a vaccine or treatment for the relatively rare strain to the clinical trial stage where it is tested on humans.
Earlier this month, a team at Oxford University in the UK announced it was launching the first trial for its ChAdOx1 BDBV vaccine, which uses the same technology as AstraZeneca's Covid-19 vaccine.
The first dose was administered to a 37-year-old volunteer named Ed Hunt in Oxford on Friday, a university spokesman told AFP.
"We've taken this vaccine candidate from concept to clinic in just eight weeks," David Pulido-Gomez of Oxford's Pandemic Sciences Institute said in a statement.
"Reaching this milestone in such a short timeframe reflects an extraordinary collaborative effort," he added.
The trial received funding from the Coalition for Epidemic Preparedness Innovations (CEPI), while the Serum Institute of India has already manufactured a stockpile of 620,000 doses.
The phase 1 trial plans to assess the safety and effectiveness of the vaccine in 50 health adults in the coming weeks. The researchers are currently recruiting more volunteers.
Given regulatory approval, the team is preparing for more clinical studies of the vaccine with partners in Uganda, Oxford said.
Several other Bundibugyo vaccine candidates are also being urgently developed towards the trial stage, while two potential treatments are being worked on.
The Ebola outbreak is the 17th in the DRC's history, but just the third caused by the Bundibugyo strain, for which there are no approved vaccines or treatments.
WHO chief Tedros Adhanom Ghebreyesus warned last week that the outbreak had over the past month "expanded faster than any previous outbreak" of Ebola.
The outbreak has remained concentrated in the vast country's mineral-rich and conflict-plagued northeastern province.
Cases of Ebola, which spreads through close contact and infected bodily fluids, have also been found in four other DRC provinces.
M.Furrer--BTB